| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Inhibrx, Inc. | 4,724,352 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | VIKING GLOBAL INVESTORS LP | Inhibrx, Inc. | 7,150,826 | 15.1% | EDGAR |
| SC 13G/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | Inhibrx, Inc. | 4,776,306 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Lappe Mark | Inhibrx, Inc. | 2,486,192 | 5.2% | EDGAR |
| SC 13G/A | 2024-02-14 | Kayyem Jon Faiz | Inhibrx, Inc. | 3,308,123 | 7.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Eckelman Brendan P. | Inhibrx, Inc. | 2,035,553 | 4.3% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Inhibrx, Inc. | 2,715,672 | 5.7% | EDGAR |
| SC 13G/A | 2024-01-23 | STATE STREET CORP | Inhibrx, Inc. | - | 3.5% | EDGAR |
| SC 13G/A | 2023-03-09 | Inhibrx, Inc. | Inhibrx, Inc. | 3,307,310 | 7.6% | EDGAR |
| SC 13G/A | 2023-03-09 | Inhibrx, Inc. | Inhibrx, Inc. | 2,155,553 | 4.9% | EDGAR |
| SC 13G/A | 2023-03-09 | Inhibrx, Inc. | Inhibrx, Inc. | 2,512,252 | 5.8% | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | Inhibrx, Inc. | 3,853,867 | 8.9% | EDGAR |
| SC 13G/A | 2023-02-14 | VIKING GLOBAL INVESTORS LP | Inhibrx, Inc. | 6,639,199 | 15.2% | EDGAR |
| SC 13G/A | 2023-02-14 | PERCEPTIVE ADVISORS LLC | Inhibrx, Inc. | 3,313,783 | 7.6% | EDGAR |
| SC 13G | 2023-02-08 | STATE STREET CORP | Inhibrx, Inc. | - | 5.8% | EDGAR |
| SC 13G | 2023-02-03 | BlackRock Inc. | Inhibrx, Inc. | 2,416,188 | 5.5% | EDGAR |
| SC 13G | 2022-10-17 | RA CAPITAL MANAGEMENT, L.P. | Inhibrx, Inc. | 3,185,831 | 8.2% | EDGAR |
| SC 13G | 2022-07-19 | PERCEPTIVE ADVISORS LLC | Inhibrx, Inc. | 1,968,744 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-14 | VIKING GLOBAL INVESTORS LP | Inhibrx, Inc. | 5,305,866 | 14.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Inhibrx, Inc. | Inhibrx, Inc. | 2,590,252 | 6.6% | EDGAR |